Key Points
- Director sale: Tyra director Robert More sold 246,871 shares on Nov. 21 at an average price of $20.25 for a total of $4,999,137.75, reducing his stake by 6.05% to 3,833,425 shares (≈$77.6M).
- Stock and analyst view: TYRA has a $1.17B market cap, reported ($0.50) EPS last quarter (in line with estimates), and carries a consensus rating of "Moderate Buy" with a $32 target price despite a one‑year range of $6.42–$22.68.
- Institutional backing: Institutional investors own about 84.14% of the company, with several hedge funds (e.g., Commodore, Vestal Point, Vanguard, Balyasny, Sio) recently increasing their positions.
Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Robert More sold 246,871 shares of the stock in a transaction on Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the sale, the director owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. This represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Tyra Biosciences Price Performance
TYRA stock opened at $21.90 on Wednesday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -11.71 and a beta of 1.12. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $22.68. The business has a fifty day moving average price of $14.86 and a 200-day moving average price of $12.10.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). As a group, analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.
Institutional Investors Weigh In On Tyra Biosciences
Hedge funds have recently modified their holdings of the business. Commodore Capital LP raised its holdings in Tyra Biosciences by 8.9% in the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company's stock worth $47,216,000 after purchasing an additional 275,000 shares during the period. Vestal Point Capital LP grew its holdings in Tyra Biosciences by 190.9% during the first quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock valued at $26,782,000 after purchasing an additional 1,889,829 shares during the period. Vanguard Group Inc. grew its holdings in Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company's stock valued at $21,267,000 after purchasing an additional 118,492 shares during the period. Balyasny Asset Management L.P. increased its position in Tyra Biosciences by 45.1% in the third quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company's stock worth $11,844,000 after buying an additional 263,199 shares in the last quarter. Finally, Sio Capital Management LLC raised its stake in shares of Tyra Biosciences by 94.5% in the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company's stock worth $7,754,000 after buying an additional 393,657 shares during the period. Institutional investors own 84.14% of the company's stock.
Wall Street Analyst Weigh In
TYRA has been the subject of several research reports. Wedbush reissued an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Thursday, November 6th. Raymond James Financial assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $35.00 target price for the company. Wall Street Zen lowered shares of Tyra Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.
View Our Latest Stock Analysis on TYRA
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
